ArticleAnnals of surgical oncology2026
Preoperative Chemotherapy with Gemcitabine and Cisplatin for Biliary Tract Cancer Does Not Affect Liver Regeneration Induced by Portal Vein Embolization.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough perioperative chemotherapy has recently been advocated for patients with biliary tract cancer (BTC) undergoing resection, little is known about its risks and efficacy in those who also require preoperative portal vein embolization (PVE) to secure residual liver capacity. This study aimed to examine liver hypertrophy and perioperative outcomes in patients with BTC treated with preoperative chemotherapy and PVE.
methodsA total of 186 patients who underwent PVE for BTC in our institution were retrospectively analyzed. Patients were divided into two groups: those who received gemcitabine and cisplatin chemotherapy after PVE (P+C group, n=57) and those who did not (P group, n=129). Propensity score matching was performed to reduce bias. Liver hypertrophy, liver function, and perioperative outcomes were compared. We also examined the frequency of chemotherapy-related adverse events.
resultsAfter matching, the degree of liver hypertrophy and the kinetic growth rates after PVE were similar between the two groups. Liver enzyme changes and indocyanine green test results also showed no significant differences. The resection rates were 88.4% in the P group and 61.4% in the P+C group. Postoperative complication rates among the resected cases were comparable between the groups. Moreover, no increase in chemotherapy-related adverse events was observed when chemotherapy was administered concurrently with PVE.
conclusionPerioperative gemcitabine and cisplatin chemotherapy in patients with BTC did not significantly suppress PVE-induced liver hypertrophy or impair liver function. It did not impact on postoperative complications or chemotherapy-related adverse events.
Indexed as
Identifiers
41492115What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.